Brief: Landos Biopharma Announces Acceptance Of Abstract On Ulcerative Colitis Study
11/01/2023 12:40
Jan 11 (Reuters) - Landos Biopharma Inc LABP.O :
* LANDOS BIOPHARMA ANNOUNCES ACCEPTANCE OF ABSTRACT ON NX-13
PHASE
1B STUDY IN ULCERATIVE COLITIS AT 18TH ANNUAL CONGRESS OF THE
EUROPEAN CROHN’S AND COLITIS ORGANIZATION
Source text for Eikon: ID:nGNX5mwcHG
Further company coverage: LABP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Landos Biopharma
See all newsLandos Biopharma Inc expected to post a loss of 100 cents a share - Earnings Preview
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Super Micro, Micron Technology, Navios Maritime
U.S. STOCKS ON THE MOVE-Landos Biopharma, Foot Locker, US energy sector
Brief: AbbVie To Acquire Landos Biopharma